All In Biotech

Drug Trial Radar · NCT01488097

Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of SBC-102 (Sebelipase Alfa) in Adult Subjects With Lysosomal Acid Lipase Deficiency

An Open Label Multicenter Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of SBC-102 in Adult Subjects With Liver Dysfunction Due to Lysosomal Acid Lipase Deficiency Who Previously Received Treatment in Study LAL-CL01

Last checked: Nov 20, 2026Latest source record: Jul 20, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

8

Actual

Start

Dec 12, 2011

Primary completion

Jun 21, 2017

Study completion Jun 21, 2017

Sponsor

Lead sponsor
Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
Sponsor type
Industry
First posted
Dec 8, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This was an extension study to Study LAL-CL01 (NCT01307098). The primary objective of the study was to evaluate the long-term safety and tolerability of sebelipase alfa in participants with liver dysfunction due to lysosomal acid lipase (LAL) deficiency.

Conditions

  • Cholesterol Ester Storage Disease (CESD)
  • Lysosomal Acid Lipase Deficiency
  • LAL-Deficiency

Interventions

  • sebelipase alfaDrug

    Sebelipase alfa is a recombinant human lysosomal acid lipase.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number Of Participants Reporting TEAEs And IARsTime frame: From after first dose administration post-Baseline through EOS during study LAL-CL04

Locations

10 sites in 5 countries. Site status is shown where the registry gives one.

  • Site not named

    Eureka, California

  • Site not named

    Sacramento, California

  • Site not named

    San Francisco, California

  • Site not named

    Minneapolis, Minnesota

  • Site not named

    New York, New York

  • Site not named

    Greater Sudbury, Ontario, Canada

  • Site not named

    Prague, Czechia

  • Site not named

    Paris, France

  • Site not named

    Leeds, United Kingdom

  • Site not named

    Salford, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.